Extractables and Leachables Testing: Key Risk Points

Extractables and leachables testing is a critical safeguard for quality control and safety teams managing single-use systems, sterile packaging, and life science consumables.

As polymer materials, additives, and process aids interact with biologics, diagnostics, or drug-contact surfaces, even trace-level migrants can create regulatory, toxicological, and product stability risks.

This article highlights the key risk points that QC and safety managers should evaluate to strengthen compliance, prevent batch failures, and support safer material selection.

Why Extractables and Leachables Testing Needs a Checklist Approach

Extractables and leachables testing rarely fails because one document is missing.

Failures usually appear when material knowledge, process conditions, toxicology, and analytical sensitivity are not connected early enough.

A checklist approach helps teams convert complex chemistry into visible decisions.

It also supports consistent reviews across single-use bags, tubing, filters, closures, diagnostic kits, and sterile barrier packaging.

In biologics and advanced therapies, the stakes are higher.

A leachable compound may affect protein aggregation, cell growth, enzyme activity, assay signal, or patient safety.

For this reason, extractables and leachables testing should begin before final supplier qualification.

Core Checklist for Extractables and Leachables Testing

Use the following checklist to structure risk reviews, laboratory planning, supplier discussions, and regulatory documentation.

• Map every product-contact component, including films, gaskets, adhesives, inks, lubricants, filters, caps, closures, tubing, connectors, and processing aids.
• Define worst-case contact conditions by reviewing temperature, time, solvent strength, pH, sterilization method, and storage duration.
• Request detailed material disclosures, formulation change controls, resin grades, additive families, and manufacturing site information from suppliers.
• Classify components by risk, focusing first on high-surface-area plastics, long-contact assemblies, and materials touching final drug product.
• Design extraction studies using aggressive but scientifically justified solvents that represent aqueous, acidic, basic, alcoholic, and nonpolar conditions.
• Select analytical platforms that cover volatile, semi-volatile, nonvolatile, elemental, and unknown organic compounds with suitable detection limits.
• Set analytical evaluation thresholds using dose, route of administration, patient population, product volume, and toxicological concern.
• Compare extractables profiles against real-use leachables data, because aggressive extraction results do not always represent clinical exposure.
• Investigate unidentified peaks promptly, especially when signals are persistent, structurally concerning, or near reporting thresholds.
• Document toxicological assessments with clear assumptions, uncertainty factors, compound identification confidence, and margin-of-safety conclusions.
• Link extractables and leachables testing results to supplier qualification, incoming inspection, validation strategy, and change control requirements.
• Review results after sterilization, aging, shipping simulation, or process scale-up, because material behavior can shift under stress.

Material Risk Points That Deserve Early Attention

Polymer Base Resin

The base resin determines the first layer of risk.

Polyethylene, polypropylene, polycarbonate, cyclic olefin polymers, fluoropolymers, and elastomers each release different chemical families.

Extractables and leachables testing should verify whether resin selection matches contact duration, solvent exposure, and sterilization method.

Additives and Processing Aids

Stabilizers, antioxidants, slip agents, plasticizers, pigments, mold-release agents, and curing residues often drive the most important peaks.

These compounds may be present at low levels, yet still matter for sensitive biologics or diagnostic assays.

A robust extractables and leachables testing plan should challenge both known additives and unexpected degradation products.

Sterilization Effects

Gamma irradiation, electron beam, ethylene oxide, steam, and dry heat can alter material chemistry.

Irradiation may generate radicals, aldehydes, ketones, or chain scission products.

Ethylene oxide can leave residues or reaction byproducts.

Therefore, extractables and leachables testing should use sterilized components matching the intended commercial process.

Application Scenarios for Life Science Consumables

Single-Use Systems for Bioprocessing

Single-use bags, mixers, tubing, and connectors present large contact surfaces.

They may contact buffers, media, intermediates, or final biologic formulations for hours or weeks.

Extractables and leachables testing in this scenario should focus on surface-area-to-volume ratios and process hold times.

Particular attention is needed for cell culture media contact.

Certain leachables can reduce viable cell density, change metabolism, or interfere with protein expression.

Sterile Packaging and Barrier Materials

Sterile packaging may not always contact liquid products directly.

However, inks, adhesives, coatings, and barrier films can still contribute volatile or semi-volatile migrants.

Extractables and leachables testing should consider long storage, transport heat, humidity, and sterilization compatibility.

For medical device packaging, the evaluation should also connect chemical safety with package integrity and microbial barrier performance.

IVD Kits and Diagnostic Reagents

Diagnostic kits can be chemically sensitive.

Migrants from plastics, foils, caps, desiccants, or labels may affect antibodies, enzymes, fluorescent beads, or assay membranes.

Here, extractables and leachables testing must support analytical performance, not only toxicological safety.

Even low-level compounds may influence background signal, calibration drift, or shelf-life claims.

Commonly Overlooked Risk Points

Assuming Supplier Data Is Always Transferable

Supplier extractables reports are valuable, but they may not represent the final application.

Different solvents, temperatures, gamma doses, or contact times can produce different profiles.

Extractables and leachables testing should verify whether vendor data matches actual process conditions.

Ignoring Small Components

Small elastomeric seals, labels, septa, and valves are easy to overlook.

Yet these parts may contain complex additives, curing agents, or adhesives.

A complete extractables and leachables testing inventory must include every material in the contact pathway.

Treating Unknown Peaks as Minor Noise

Unknown compounds create regulatory and toxicological uncertainty.

A small peak can still matter when potency is high, dosing is repeated, or patients are vulnerable.

Extractables and leachables testing should include a practical escalation path for structural identification.

Separating Chemical Safety from Product Quality

Chemical safety and product performance are connected.

A compound may be below toxicological concern but still affect aggregation, adsorption, appearance, or diagnostic accuracy.

Effective extractables and leachables testing should be reviewed alongside stability and compatibility data.

Practical Execution Tips for Stronger Control

1. Start with a material-contact map before commissioning laboratory work, so testing scope follows real exposure rather than assumptions.
2. Use risk ranking to prioritize components with high surface area, long contact, soft polymers, adhesives, or final-product exposure.
3. Align extraction solvents with formulation chemistry, including aqueous buffers, surfactants, alcohol content, oils, and extreme pH conditions.
4. Confirm detection limits before testing begins, because weak sensitivity can create false confidence in low-risk conclusions.
5. Review chromatograms, not only summary tables, to spot recurring unknowns, solvent artifacts, or batch-specific deviations.
6. Build change-control triggers for resin grade changes, sterilization changes, supplier transfers, tooling updates, and packaging redesigns.
7. Connect extractables and leachables testing with stability, biocompatibility, process validation, and complaint trend reviews.

Decision Criteria for Accepting or Rejecting Materials

Material acceptance should not rely on one number.

A strong decision combines chemical identity, exposure estimate, toxicological profile, analytical confidence, and product impact.

When uncertainty remains, targeted leachables studies can provide stronger evidence than additional aggressive extraction alone.

This is especially important for final containers, drug-contact assemblies, and sensitive biologic formulations.

Summary and Action Guide

Extractables and leachables testing is not only a regulatory exercise.

It is a practical system for controlling chemical risk across materials, suppliers, processes, and product lifecycles.

The strongest programs begin with a full contact map, then apply risk ranking, justified extraction conditions, sensitive analytics, and toxicological review.

They also connect chemical findings with stability, biological performance, diagnostic accuracy, and sterile packaging reliability.

For the next review cycle, start by updating the component inventory.

Then identify high-risk materials, verify supplier data, and define where targeted leachables studies are needed.

A disciplined extractables and leachables testing checklist helps prevent late-stage surprises and supports safer, cleaner life science consumables.